manumycin has been researched along with Breast-Neoplasms* in 3 studies
3 other study(ies) available for manumycin and Breast-Neoplasms
Article | Year |
---|---|
Manumycin polyketides act as molecular glues between UBR7 and P53.
Molecular glues are an intriguing therapeutic modality that harness small molecules to induce interactions between proteins that typically do not interact. However, such molecules are rare and have been discovered fortuitously, thus limiting their potential as a general strategy for therapeutic intervention. We postulated that natural products bearing one or more electrophilic sites may be an unexplored source of new molecular glues, potentially acting through multicovalent attachment. Using chemoproteomic platforms, we show that members of the manumycin family of polyketides, which bear multiple potentially reactive sites, target C374 of the putative E3 ligase UBR7 in breast cancer cells, and engage in molecular glue interactions with the neosubstrate tumor-suppressor TP53, leading to p53 transcriptional activation and cell death. Our results reveal an anticancer mechanism of this natural product family, and highlight the potential for combining chemoproteomics and multicovalent natural products for the discovery of new molecular glues. Topics: Antineoplastic Agents; Breast Neoplasms; Cell Line, Tumor; Cross-Linking Reagents; Drug Discovery; Female; Gene Expression Regulation, Neoplastic; Gene Knockdown Techniques; Humans; Molecular Conformation; Molecular Structure; Polyenes; Polyketides; Polyunsaturated Alkamides; Static Electricity; Structure-Activity Relationship; Tumor Suppressor Protein p53; Ubiquitin-Protein Ligases | 2020 |
Manumycin A inhibits triple-negative breast cancer growth through LC3-mediated cytoplasmic vacuolation death.
Therapy resistance can be attributed to acquisition of anti-apoptotic mechanisms by the cancer cells. Therefore, developing approaches that trigger non-apoptotic cell death in cancer cells to compensate for apoptosis resistance will help to treat cancer effectively. Triple-negative breast cancers (TNBC) are among the most aggressive and therapy resistant to breast tumors. Here we report that manumycin A (Man A), an inhibitor of farnesyl protein transferase, reduces cancer cell viability through induction of non-apoptotic, non-autophagic cytoplasmic vacuolation death in TNBC cells. Man A persistently induced cytoplasmic vacuolation and cell death through the expression of microtubule-associated protein 1 light chain 3 (LC3) and p62 proteins along with endoplasmic reticulum (ER) stress markers, Bip and CHOP, and accumulation of ubiquitinated proteins. As inhibitors of apoptosis and autophagy failed to block cytoplasmic vacuolation and its associated protein expression or cell death, it appears that these processes are not involved in the death induced by Man A. Ability of thiol antioxidant, NAC in blocking Man A-induced vacuolation, death and its related protein expression suggests that sulfhydryl homeostasis may be the target of Man A. Surprisingly, normal human mammary epithelial cells failed to undergo cytoplasmic vacuolation and cell death, and grew normally in presence of Man A. In conjunction with its in vitro effects, Man A also reduced tumor burden in vivo in xenograft models that showed extensive cytoplasmic vacuoles and condensed nuclei with remarkable increase in the vacuolation-associated protein expression together with increase of p21, p27, PTEN and decrease of pAkt. Interestingly, Man A-mediated upregulation of p21, p27 and PTEN and downregulation of pAkt and tumor growth suppression were also mimicked by LC3 knockdown in MDA-MB-231 cells. Overall, these results suggest novel therapeutic actions by Man A through the induction of non-apoptotic and non-autophagic cytoplasmic vacuolation death by probably affecting ER stress, LC3 and p62 pathways in TNBC but not in normal mammary epithelial cells. Topics: Adaptor Proteins, Signal Transducing; Animals; Anti-Bacterial Agents; Apoptosis; Breast Neoplasms; Cell Line; Cyclin-Dependent Kinase Inhibitor p21; Cyclin-Dependent Kinase Inhibitor p27; Drug Resistance, Neoplasm; Endoplasmic Reticulum Chaperone BiP; Endoplasmic Reticulum Stress; Epithelial Cells; Farnesyltranstransferase; Female; Heat-Shock Proteins; Humans; Mice; Mice, Nude; Microtubule-Associated Proteins; Polyenes; Polyunsaturated Alkamides; Proto-Oncogene Proteins c-akt; PTEN Phosphohydrolase; Sequestosome-1 Protein; Transcription Factor CHOP; Transplantation, Heterologous; Ubiquitination | 2013 |
Expression of rTSbeta as a 5-fluorouracil resistance marker in patients with primary breast cancer.
Expression of thymidylate synthase (TS) in tumor cells is frequently suggested as an important prognostic factor for patients scheduled for chemotherapy with 5-fluorouracil (5-FU). However, clinical evidence does not fully support such an anticipation. We studied the expression of rTSbeta, a reverse orientation gene of TS, as a 5-FU resistance marker in patients with primary breast cancer. Expression of rTSbeta was examined in 129 patients with newly diagnosed breast cancer and five breast cancer cell lines by immunohistochemistry, immunocytochemistry and immunoblotting. Clinically, expression of rTSbeta was found to correlate with survival of the patients (p=0.023) when patients received chemotherapeutic regimen containing 5-FU. In vitro, rTSbeta expression was found to correlate with 5-FU resistance in breast cancer cell lines. Notably, in the 5-FU-resistant cells, rTSbeta was identified in the nucleus, whereas in the 5-FU-sensitive cells, rTSbeta was found in the cytoplasm. Nuclear localization of rTSbeta was further found to be associated with protein farnesylation. Therefore, nuclear expression of rTSbeta could be a novel 5-FU resistance marker in patients with primary breast cancer. Topics: Adult; Aged; Antimetabolites, Antineoplastic; Antisense Elements (Genetics); Biomarkers; Breast Neoplasms; Drug Resistance, Neoplasm; Female; Fluorouracil; Humans; Middle Aged; Polyenes; Polyunsaturated Alkamides; Prenylation; Thymidylate Synthase | 2008 |